Future Directions in Artificial Intelligence

Predictive Value of the Total Bilirubin and CA50 Screened Based on Machine Learning for Recurrence of Bladder Cancer Patients

Purpose

Recurrence is the main factor for poor prognosis of bladder cancer. Therefore, it is necessary to develop new biomarkers to predict the prognosis of bladder cancer. In this study, we used machine learning (ML) methods based on a variety of clinical variables to screen prognostic biomarkers of bladder cancer.

Patients and Methods

A total of 345 bladder cancer patients were participated in this retrospective study and randomly divided into training and testing group. We used five supervised clustering ML algorithms: decision tree (DT), random forest (RF), adaptive boosting (AdaBoost), gradient boosting machine (GBM), and extreme gradient boosting (XGBoost) to obtained prediction information through 34 clinical parameters.

Results

By comparing five ML algorithms, we found that total bilirubin (TBIL) and CA50 had the best performance in predicting the recurrence of bladder cancer. In addition, the combined predictive performance of the two is superior to the performance of any single indicator prediction.

Conclusion

ML technology can evaluate the recurrence of bladder cancer. This study shows that the combination of TBIL and CA50 can improve the prognosis prediction of bladder cancer recurrence, which can help clinicians make decisions and develop personalized treatment strategies.

Artificial Intelligence in the Future Landscape of Pediatric Neuroradiology: Opportunities and Challenges

This paper will review how artificial intelligence (AI) will play an increasingly important role in pediatric neuroradiology in the future. A safe, transparent, and human-centric AI is needed to tackle the quadruple aim of improved health outcomes, enhanced patient and family experience, reduced costs, and improved well-being of the healthcare team in pediatric neuroradiology. Equity, diversity and inclusion, data safety, and access to care will need to always be considered. In the next decade, AI algorithms are expected to play an increasingly important role in access to care, workflow management, abnormality detection, classification, response prediction, prognostication, report generation, as well as in the patient and family experience in pediatric neuroradiology. Also, AI algorithms will likely play a role in recognizing and flagging rare diseases and in pattern recognition to identify previously unknown disorders. While AI algorithms will play an important role, humans will not only need to be in the loop, but in the center of pediatric neuroimaging. AI development and deployment will need to be closely watched and monitored by experts in the field. Patient and data safety need to be at the forefront, and the risks of a dependency on technology will need to be contained. The applications and implications of AI in pediatric neuroradiology will differ from adult neuroradiology.

Artificial Intelligence in Nuclear Medicine: Opportunities, Challenges, and Responsibilities Toward a Trustworthy Ecosystem

Trustworthiness is a core tenet of medicine. The patient-physician relationship is evolving from a dyad to a broader ecosystem of health care. With the emergence of artificial intelligence (AI) in medicine, the elements of trust must be revisited. We envision a road map for the establishment of trustworthy AI ecosystems in nuclear medicine. In this report, AI is contextualized in the history of technologic revolutions. Opportunities for AI applications in nuclear medicine related to diagnosis, therapy, and workflow efficiency, as well as emerging challenges and critical responsibilities, are discussed. Establishing and maintaining leadership in AI require a concerted effort to promote the rational and safe deployment of this innovative technology by engaging patients, nuclear medicine physicians, scientists, technologists, and referring providers, among other stakeholders, while protecting our patients and society. This strategic plan was prepared by the AI task force of the Society of Nuclear Medicine and Molecular Imaging.